COVID-19: Indian Immunologicals to start drug substance production for Covaxin from June

By: |
May 29, 2021 10:06 AM

IIL is also working on another COVID -19 vaccine and the animal trials are underway and is expected to come out next year for human vaccination, he noted.

It also said that the calf serum is particularly beneficial in order to facilitate growth of a difficult to grow disease-causing virus or micro-organisms.It also said that the calf serum is particularly beneficial in order to facilitate growth of a difficult to grow disease-causing virus or micro-organisms.

Indian Immunologicals Ltd, a city-based facility under the National Dairy Development Board, has announced its plans to begin the production of drug substance meant for COVID-19 vaccine Covaxin from June 15, and despatch the first batch to Bharat Biotech by July.

IILs Managing Director K Anand Kumar in a release on Friday said the firm is expected to produce the drug substance initially for 2-3 million doses per month. It will be scaled up to 7 million later in the year and eventually to 15 million.

To further increase the COVID-19 vaccine manufacturing capacity, Bharat Biotech had said it partnered with IIL to make the drug substance for Covaxin.

The technology transfer process was well underway and IILhas the capabilities and expertise to manufacture inactivated viral vaccines at commercial scale and under biosafety containment, the drug had said.

Kumar said IIL is converting its Karkapatla manufacturing unit near here into a Biosafety Level -3 (BSL3) facility for the production of the drug substance and also taking up construction of another block.

IIL is also working on another COVID -19 vaccine and the animal trials are underway and is expected to come out next year for human vaccination, he noted.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1South African regulator approves Pfizer booster vaccine after surge in COVID cases
2WHO: Omicron could spread faster but it’s still not certain
3UK PM Boris Johnson moves to Plan B COVID measures as 131 more Omicron cases recorded